GlaxoSmithKline CEO Walmsley Says Tesaro Drug Can Give Ovarian Cancer Victims More Time

The CEO of GSK discusses the company's recent activities, including the acquisition of Tesoro, strategic partnerships, and joint ventures. She highlights the focus on improving shareholder returns and patient impact, managing debt, and preparing for Brexit. The discussion also covers the potential of Tesoro's assets, the importance of generics, and the strategic direction for GSK's pharma and consumer healthcare businesses.

What are the key focuses for GSK in the upcoming years as mentioned in the interview?

What is the significance of the Advair generic to GSK's pipeline?

How does the CEO view the role of generics in the pharmaceutical market?